PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32615180-1	2020	The goal of our study was to determine whether GPR55 agonists, O-1602, could reverse the cyclophosphamide (CYP)-induced changes in cystometric and inflammatory parameters, indicative of the development of bladder inflammation and overactivity.	Cyclophosphamide	89-105	G protein-coupled receptor 55	Rattus norvegicus	47-52	
32615180-2	2020	If confirmed, the stimulation of novel cannabinoid receptor - GPR55, could be a reasonable strategy as a treatment of CYP-induced haemorrhagic cystitis.	Cyclophosphamide	118-121	G protein-coupled receptor 55	Rattus norvegicus	62-67	
32615180-7	2020	Intravenous administration of the GPR55 agonist to animals that received CYP significantly decreased Evans Blue extravasation and increased urothelium thickness.	Cyclophosphamide	73-76	G protein-coupled receptor 55	Rattus norvegicus	34-39	
32615180-1	2020	The goal of our study was to determine whether GPR55 agonists, O-1602, could reverse the cyclophosphamide (CYP)-induced changes in cystometric and inflammatory parameters, indicative of the development of bladder inflammation and overactivity.	Cyclophosphamide	107-110	G protein-coupled receptor 55	Rattus norvegicus	47-52